NAFLD的发病机制与新型治疗药物研发

Pathogenesis of Nonalcoholic Fatty Liver Disease and Development of New Therapeutic Drugs

NAFLD(nonalcoholic fatty liver disease)是一种常见的慢性肝脏疾病。随着病情的发展,NAFLD还会引发2型糖尿病、心血管疾病等。目前较为常见的治疗药物包括调脂类药物、过氧化物酶体增长因子活化受体激动剂、保肝抗炎类药物等,尚缺乏针对NAFLD的特效药物。近年来发现,NAFLD的发病机制与胰岛素抵抗密切相关,促胰岛素分泌型抗菌肽具有缓解胰岛素抵抗和治疗NAFLD的功效。该文综述了NAFLD发病机制和治疗药物的研究进展,并结合作者实验室相关的研究工作,分析了促胰岛素分泌型抗菌肽治疗NAFLD的优势。

NAFLD (nonalcoholic fatty liver disease) is a common chronic fatty liver disease.With the development of the disease,it can also cause type 2 diabetes,cardiovascular disease and so on.At present,the common treatments include lipid-lowering drugs,peroxisome growth factor activating receptor agonists,liver-protecting anti-inflammatory drugs,etc.But there is a lack of specific drugs for NAFLD.It is found that the pathogenesis of NAFLD is closely related to insulin resistance by researches.Antibacterial peptides promoting insulin can alleviate insulin resistance and treat NAFLD.This article reviews the pathogenesis of NAFLD and researches of therapeutic drugs.Combined with the researches of the author’s laboratory,the advantages of insulin-promoting antibacterial peptides in the treatment of NAFLD are analzed.